Drugs / NCX 470
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03657797 | Aug 2018 → Aug 2019 | ocular hypertension, open-angle glaucoma | Nicox Ophthalmics, Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04630808 | Nov 2020 → Apr 2025 | ocular hypertension, open-angle glaucoma | Nicox Ophthalmics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04445519 | Jun 2020 → Sep 2022 | ocular hypertension, open-angle glaucoma | Nicox Ophthalmics, Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05938699 Comparator | Dec 2023 → Mar 2025 | open-angle glaucoma | Nicox Ophthalmics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NCX 470 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03657797 ↗ |
| Known as | bimatoprost | “A phase 3 adaptive dose selection trial of NCX 470, a nitric oxide-donating bimatoprost for open-angle glaucoma or ocular hypertension: The MONT BLANC study.” PMID 39477206 ↗ Oct 2024 |
| Route | Topical | “dosed topically to both eyes once daily” PMID 39477206 ↗ Oct 2024 |